Biologics for CNS/ Neuromusc Dis: 91.9% of denials overturned
In 37 California IMR decisions from 2016 to 2025, reviewers overturned 34 (91.9%). In the last five years: 93.1% of 29. 31 were medical-necessity disputes, 6 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 2 | 100.0% |
| 2022 | 1 | 100.0% |
| 2023 | 2 | 50.0% |
| 2024 | 12 | 100.0% |
| 2025 | 12 | 91.7% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 20 | 100.0% | 91.9% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 10 | 90.0% | 91.9% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 6 | 100.0% | 91.9% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Briumvi 150mg/6mL vial on day 1, 450mg on day 15, then 450mg every 24 weeks. In this case, the patient has been diagnosed with SPMS. A review of the record establishes that the patient has tried and failed treatment with ocrelizumab and Mayzent. The medical literature supports …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Emgality.One study recommended daily preventative medication such as calcitonin gene-related peptide (CGRP) agents or gepants for migraine prevention. The International Headache Society (IHS) supports treatment with preventive medications for patients with more than four migraines per month. The American Headache Society (AHS) …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested authorization and coverage for Leqembi. Leqembi is a U.S. Food and Drug Administration (FDA)-approved treatment for Alzheimer’s disease in patients with early-stage disease, including mild cognitive impairment or mild dementia due to Alzheimer’s disease. Clinical guidelines and medical literature support its use in appropriately selected patients with …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for rituximab injections. In this case, there is no established diagnosis of Sjögren’s syndrome, connective tissue disease, or another immune-mediated condition for which rituximab would be appropriate. The patient’s autoimmune serologies, including antinuclear antibody, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, and prior Sjögren’s …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Biologics denials for CNS/ Neuromusc Dis overturned?
In 37 California IMR decisions from 2016 to 2025, reviewers overturned 34 (91.9%). In the last five years: 93.1% of 29. 31 were medical-necessity disputes, 6 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.